Several inhibitors targeting the PI3K pathway have been approved by the FDA (copanlisib, idelalisib, umbraniesib, duvelisib, alpelisib), and many other compounds are being tested in various cancers, including melanoma (Mishra et al. 2021). This evidence concerns the gene PIK3CA and cancer.